

ForwardHealth **ALERT**

Wisconsin serving you



TO

Blood Banks, Community Health Centers, Hospital Providers, Independent Labs, Nurse Practitioners, Nurses in Independent Practice, Physician Assistants, Physician Clinics, Physicians, Rural Health Clinics, Tribal Federally Qualified Health Centers, HMOs and Other Managed Care Programs

REGARDING

COVID-19 and Influenza Laboratory Procedure Codes 87636, 87637, and 87428 Will Be Allowable

COVID-19 and Influenza Laboratory Procedure Codes 87636, 87637, and 87428 Will Be Allowable

Effective for dates of service on and after August 1, 2021, ForwardHealth will accept the following Current Procedural Terminology laboratory procedure codes from eligible providers who test patients for COVID-19 and influenza virus types A and B concurrently:

- 87636 (Infectious agent detection by nucleic acid [DNA or RNA]; severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [Coronavirus disease (COVID-19)] and influenza virus types A and B, multiplex amplified probe technique)
- 87637 (Infectious agent detection by nucleic acid [DNA or RNA]; severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] [Coronavirus disease (COVID-19)], influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique)
- 87428 (Infectious agent antigen detection by immunoassay technique, [eg, enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), fluorescence immunoassay (FIA), immunochemiluminometric assay (IMCA)] qualitative or semiquantitative; severe acute respiratory syndrome coronavirus [eg, SARS-CoV, SARS-CoV-2 (COVID-19)] and influenza virus types A and B)

Also effective for dates of service on and after August 1, 2021, ForwardHealth will accept Current Procedural Terminology procedure codes 87636, 87637, and 87428 submitted with modifier QW (Clinical Laboratory Improvement Amendment-waived test) from facilities that have a current [Clinical Laboratory Improvement Amendment \(CLIA\) certificate of waiver](#).

Providers should refer to the U.S. Food and Drug Administration's guidance on [Emergency Use Authorizations](#) for COVID-19 for information about the appropriate settings in which an Emergency Use Authorization-authorized test may be used.